Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | BRD2 | P25440 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PER2 | O15055 | 2/20 | 0.35 |
| ▸ | INMT | O95050 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL19638241 | 0.89 | MAPK1 (0.39) | BRD4BRD2MAPK1CYP1A2TDP1 | |
| SCHEMBL82580 | 0.89 | — | — | |
| SCHEMBL916157 | 0.86 | BRD4 (0.50) | BRD4BRD2PER2INMTCRY2 | |
| Fluoride SCHEMBL20741987 | 0.86 | BRD4 (0.50) | BRD4BRD2PER2INMTCRY2 | |
| Bromide SCHEMBL7186245 | 0.86 | BRD4 (0.50) | BRD4BRD2PER2INMTCRY2 | |
| SCHEMBL8272670 | 0.83 | BRD4 (0.52) | BRD4BRD2PER2INMTSMN1; SMN2 | |
| Benzene SCHEMBL7856891 | 0.81 | BRD4 (0.46) | BRD4BRD2PER2INMTCRY2 | |
| Cyclohexane SCHEMBL5696269 | 0.77 | BRD4 (0.46) | BRD4BRD2INMT | |
| Hydrogen Peroxide SCHEMBL28763582 | 0.77 | BRD4 (0.39) | BRD4BRD2MAPK1PER2CRY2 | |
| Dimethyl Sulfoxide SCHEMBL5801799 | 0.77 | BRD4 (0.42) | BRD4BRD2PER2INMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212195-A1 | COMPOUNDS, CONJUGATES, AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-07-06 | — | — | US | disclosed |
| US-11535634-B2 | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-12-27 | — | — | US | disclosed |
| US-20200385407-A1 | COMPOUNDS, CONJUGATES, AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2020-12-10 | — | — | US | disclosed |
| WO-2020247054-A1 | COMPOUNDS, CONJUGATES, AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212195-A1 | COMPOUNDS, CONJUGATES, AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES AND USES THEREOF | DNPEP, DHPS, NPEPPS | BRD4 2197/4885BRD2 3128/4885MAPK1 4236/4885 |
| US-11535634-B2 | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof | DNPEP, DHPS, NPEPPS | BRD4 2197/4885BRD2 3128/4885MAPK1 4236/4885 |
| US-20200385407-A1 | COMPOUNDS, CONJUGATES, AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES AND USES THEREOF | DNPEP, DHPS, NPEPPS | BRD4 2197/4885BRD2 3128/4885MAPK1 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.